European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK
about
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.Physicochemical and biological characterization of 1E10 anti-idiotype vaccine.Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Physicochemical characterization of Remsima.Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein productsGlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.Biosimilars: how similar?Comprehensive tracking of host cell proteins during monoclonal antibody purifications using mass spectrometry.Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.Biosimilar, biobetter and next generation therapeutic antibodiesApproval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry.MS in the analysis of biosimilars.Implications of the development of biosimilars for cancer treatment.Biosimilars: Imitation Games.9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.
P2860
Q30399745-3C285C30-5A97-49F8-BE70-1BA07A076F68Q30406304-A4AC2FB5-F2AF-4341-BF49-DDE410BEB183Q34080417-61448B86-BE36-4F9C-B505-BED4172B2333Q35232337-36AA9846-1F98-4785-B98B-FDA06C9C60AAQ35992488-4B66F0DB-BF83-4CC9-BC77-A03F05CE7DA0Q36213623-0AF33ADD-A06E-4C49-8984-8934C085BAEAQ36411858-89F37478-3C61-4BDC-9EF5-54A15CB0E2E1Q38028654-C397A565-F250-4EA8-85E8-3490EC1C3154Q38151938-92693AE5-C14F-467E-BE32-316BFA7BF3DCQ39297761-6AF14242-2B08-4A84-BFAF-466D64220EF8Q41177029-4663ED6E-B2F6-450E-8422-4E1B910EFFE0Q42333450-9F9B001F-217E-4154-9398-D6951BCB4B2DQ42732007-5CC45448-A2F9-4A72-985A-20896F6A0BA6Q42846272-01D176E4-9E76-4B98-9662-81C08F473E95Q42869354-6C981109-9E59-463B-A5E5-CE55AF27083BQ42906654-59D3B637-B1C9-4D5B-8184-54A23C39C0EDQ44031303-E2C8463B-79D2-4B32-9D5C-1F1E67CE40C4Q45195831-9606656C-D4C6-48B2-9D8A-F87FE39944A5Q47884525-F7A14E33-46CA-4007-8FA9-5C1E13D384A9Q51238255-60E8F304-D371-4FEC-A0AD-CA231372CD66
P2860
European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
European Medicines Agency work ...... dies: July 2, 2009, London, UK
@en
European Medicines Agency work ...... dies: July 2, 2009, London, UK
@nl
type
label
European Medicines Agency work ...... dies: July 2, 2009, London, UK
@en
European Medicines Agency work ...... dies: July 2, 2009, London, UK
@nl
prefLabel
European Medicines Agency work ...... dies: July 2, 2009, London, UK
@en
European Medicines Agency work ...... dies: July 2, 2009, London, UK
@nl
P2860
P356
P1476
European Medicines Agency work ...... dies: July 2, 2009, London, UK
@en
P2093
Alain Beck
Harish Iyer
P2860
P304
P356
10.4161/MABS.1.5.9630
P577
2009-09-25T00:00:00Z